Additional file 1: Figure S1. of The mixed-lineage kinase 3 inhibitor URMC-099 facilitates microglial amyloid-β degradation

Abstract

URMC-099 treatment for 3, 24, or 48 h has no effect on microglial viability by using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. Data are presented as mean ± SEM. (TIF 1588 kb